Table 3 Effect of SSRI dose on modelled proportions of responders and remitters defined using commonly proposed cutoffs based on remaining symptoms in SSRI- and placebo-treated patients; n = 876 (suboptimal doses); n = 1299 (optimal doses); and n = 753 (placebo).

From: Impact of chosen cutoff on response rate differences between selective serotonin reuptake inhibitors and placebo

  

Suboptimal doses

   

Optimal doses

   

Criterion

Placebo

SSRI

Difference

p

Odds ratio (95% Cl)

SSRI

Difference

p

Odds ratio (95% Cl)

≤50% HDRS-17

43.1%

51.0%

7.9%

0.02

1.38 (1.06–1.78)

61.2%

18.1%

<0.0001

2.08 (1.62–2.67)

≤50% HDRS-6

43.7%

54.2%

10.5%

0.001

1.53 (1.18–1.97)

66.0%

22.3%

<0.0001

2.50 (1.95–3.21)

≤80% HDRS-17

11.0%

17.0%

6.0%

0.007

1.65 (1.15–2.39)

21.2%

10.1%

<0.0001

2.17 (1.53–3.07)

≤80% HDRS-6

11.4%

17.1%

5.6%

0.006

1.60 (1.14–2.22)

20.6%

9.2%

<0.0001

2.01 (1.46–2.77)

≤7 HDRS-17

24.6%

33.1%

8.5%

0.005

1.52 (1.14–2.03)

39.2%

14.7%

<0.0001

1.98 (1.51–2.62)

≤4 HDRS-6

27.4%

38.5%

11.2%

0.0003

1.66 (1.26–2.19)

45.1%

17.8%

<0.0001

2.18 (1.67–2.85)

0 Depressed mood

15.4%

26.4%

11.0%

<0.0001

1.97 (1.41–2.76)

34.3%

18.8%

<0.0001

2.86 (2.07–3.94)

  1. Suboptimal doses defined as citalopram 10–20 mg, sertraline 50 mg, paroxetine 10 mg; optimal doses as citalopram 30–40 mg, sertraline 100–400 mg, paroxetine 20–40 mg. These data have been partly reported in a previous publication [6].
Back to article page